Design Therapeutics, Inc.
DSGN · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | – | $191,616 | $219,085 | $349,728 |
| - Cash | $15,088 | $19,703 | $13,667 | $22,563 |
| + Debt | $877 | $1,102 | $2,141 | $2,334 |
| Enterprise Value | – | $173,015 | $207,559 | $329,499 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | -$14,589 | -$152 | $0 | $0 |
| % Margin | – | – | – | – |
| EBITDA | -$16,842 | -$18,931 | -$20,259 | -$16,545 |
| % Margin | – | – | – | – |
| Net Income | -$16,997 | -$19,083 | -$17,715 | -$13,651 |
| % Margin | – | – | – | – |
| EPS Diluted | -0.3 | -0.34 | -0.31 | -0.24 |
| % Growth | 11.8% | -9.7% | -29.2% | – |
| Operating Cash Flow | -$11,162 | -$14,441 | -$16,789 | -$9,860 |
| Capital Expenditures | $0 | -$87 | -$72 | $0 |
| Free Cash Flow | -$11,162 | -$14,528 | -$16,861 | -$9,860 |